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 ABSTRACT 
 
 
Background: Despite significant advances in the treatment and management of breast cancer, 
young women diagnosed before the age of 40 have worse outcomes as compared to older 
women with similar cancers. Many posit that this occurrence is related to a propensity to 
develop more biologically aggressive tumors, while others attribute these differences to the 
influences of estrogen on this young cohort.  Nevertheless, many of the therapeutic measures 
offered to young women are based on evidence derived from studies of older, post-menopausal 
women.   
Objective: To determine whether locoregional management of early-stage invasive breast 
cancer is associated with long-term survival outcomes in young women during the era of 
modern multimodal therapies. 
Methods: A systematic review of retrospective cohort studies published within the last 10 years.  
Results:  Although younger women who undergo breast-conserving therapy (BCT) have higher 
rates of local recurrence (LR), this review indicates that either there is a slight survival 
advantage after BCT compared to mastectomy (M), or that there is no survival difference based 
on these interventions.  
Conclusion:  Presently, there is insufficient evidence to determine whether younger women 
should continue to undergo more aggressive local treatment approaches, emphasizing the need 
for prospective controlled trials to generate more reliable information on the magnitude of 
survival benefits of BCT and M in young women.  
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 INTRODUCTION 
Management of breast cancer in young women is fraught with a complexity of issues distinct 
from those encountered in older patients.  Young patients experience an abrupt disruption of 
their menstrual cycle and fertility as a result of chemotherapy.  Temporary or premature 
menopause compounded with hormonal therapy (when indicated) lead to symptoms of fatigue, 
hot flashes, and increase the risk of uterine cancer, deep vein thrombosis, and depression 
among others.  Some women are not afforded a chance for fertility preservation due to the 
aggressive nature of the disease in this young cohort or due to the steep costs of this 
intervention.  Body image issues are amplified over the course of treatment as young patients 
invariably experience multiple side effects of treatment, including hair loss, deforming surgeries, 
nail changes, steroid-induced weight gain, skin changes and fibrosis related to radiation therapy 
(XRT), and lymphedema.  Patient preferences regarding local management and subsequent 
reconstruction options allow select patients to have some control during the arduous treatment 
journey.  This option is contingent upon evidence that long-term outcomes associated with 
breast-conserving therapy (BCT) are not different than those who undergo mastectomy (M).  
 
Scientists, surgeons, and physicians have made great strides in local and systemic treatment of 
breast cancer over the past three decades.  Surgeons have moved beyond the Halstedian era 
of aggressive surgical interventions as it became apparent that extirpation of the tumor with 
extensive resection of surrounding tissue, did not improve survival in all patients.  The 
movement towards BCT began in Germany and was slowly adopted by some U.S. surgeons 
over the following decades.  The divergent philosophies of surgeons practicing traditional 
Halstedian radical mastectomies and those performing breast-conserving therapy catalyzed the 
call for evidence, ultimately leading to prospective randomized trials comparing BCT to M (1).  
Six landmark prospective randomized trials compared survival outcomes in patients who 
underwent BCT versus M.  These trials included the MILAN 1 Trial conducted at the Milan
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Cancer Institute (1973-1980), the National Surgical Adjuvant Breast and Bowel Project (NSABP) 
B-06 Trial, the European Organization for Research and Treatment of Cancer (EORTC) 10801 
Trial, The Danish Breast Cancer Cooperative Group Trial, the National Cancer Institute Trial, 
and the Institut Gustave-Roussy Breast Cancer Group Trial,  No survival differences were 
detected in any of the studies; however, only a small percentage of the study subjects were 
young women.  There are no prospective randomized trials that examined the relationship 
between local treatment approach and long-term survival among young breast cancer patients 
(2-7). 
 
Chemotherapeutic regimens, including the types of drugs, doses, and frequency of 
administration continue to be challenged and improved.  Chemotherapy for breast cancer has 
evolved to include cyclophosphamide (C) to the traditional regimen of methotrexate (M), and 5-
Flouro Uracil (F), leading to improvement in survival outcomes (8).   In the late 1990’s, 
anthracycline-based (A) regimens were shown to further improve survival over CMF, namely in 
women with hormone receptor negative or triple negative breast cancers (9). More recently, 
treatment includes the addition of taxanes (T), which are used in both primary and recurrent 
breast cancer. Polychemotherapy confers considerable benefits in premenopausal patients.  
Regimens of TAC or TC have mostly replaced the use of CMF (10). In addition, radiation 
therapy (XRT) approaches, indications, and techniques, have evolved to more precisely 
irradiate the involved region while decreasing the amount of unwanted radiation to the 
underlying lungs and heart.    
 
Assays for estrogen and progesterone receptor (ER and PR) positive tumors have been 
developed during the duration of the studies, and refined since their conclusion.  
Recommendations for the use of hormonal therapy in young premenopausal women with 
estrogen receptor-positive cancers lagged behind their older counterparts.  Modern assay 
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techniques allow us to detect over-expression of human epidermal growth factor receptor 
(HER2/neu) on breast cancer cells (commonly found in young patients), which then identifies 
women who are eligible for drugs that successfully target affected cells and have improved 
prognosis in this subgroup (11).  Mapping of sentinel lymph nodes safely predicts involvement 
of remaining lymph nodes and decreases unnecessary surgery in women with early-stage 
breast cancer (12-14).  Thorough evaluation of sentinel lymph nodes became more feasible, 
since there were fewer nodes to examine with this technique.  Improvements in pathologic 
staging techniques with the addition of immunohistochemistry (IHC) and reverse transcriptase 
polymerase chain reaction (RT-PCR ); both have allowed for discovery of small foci or 
micrometastasis (15-16).  The International Breast Cancer Study Group delineated the 
association between the presence of micrometastasis and unfavorable long-term outcomes. 
Prognostic importance of occult axillary lymph node micrometastasis from breast cancers (17). 
In 2003, the American Joint Commission on Cancer (AJCC) revised the criteria for breast 
cancer staging to include this indicator (18). These techniques could effectively upstage many 
women that may have been considered early-stage, prior to the employment of these advanced 
procedures (19).  
 
METHODS 
Search Algorithm 
I began this study by searching for prospective controlled trials on the local management of 
breast cancer in women diagnosed before the age of 35. Notably, the landmark prospective 
studies on the influence of local management approach on breast cancer outcomes recruited 
women diagnosed at all ages. Although the landmark trials have abundant long-term follow-up 
data, systemic therapies, surgical techniques, and radiation approaches have advanced in the 
last 30 years. Therefore, I developed my search strategy to reflect the influence of local breast 
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cancer treatment on long-term survival outcomes of young women in the setting of modern 
evidence-based practice.  
 
I queried the PUBMED database to identify pertinent articles published between January 2003 
(to reflect significant changes in chemotherapy regimens and the development of Herceptin in 
the late 1990s and early 2000s) and January 2013.   This would produce a literature database 
reflecting the most current multimodal treatments.  I searched the following Medical Subject 
Headings (breast neoplasms/surgery or breast neoplasms/therapy) and (mastectomy or 
segmental mastectomy) and (follow up studies or cohort studies) and young adult.  I finalized 
the search terms on April 17, 2013 and finalized the search itself on June 20, 2013. I also 
supplemented these sources by hand searching bibliographies. 
 
As there were no prospective studies designed to focus specifically on outcomes for young 
women in the current era of multimodal therapies, I reviewed retrospective analyses published 
in the last 10 years that examined the effect of local management of early-stage breast cancer 
on survival in young women who were diagnosed before the age of 35.  This search did not 
yield any literature, so I expanded the search to include women diagnosed before the age of 40. 
The search was limited to studies conducted in Western nations that are likely to employ similar 
treatment modalities.  I excluded studies that included male breast cancer patients and 
manuscripts that were not written in English.  I rejected studies that evaluated the effects of 
local management in young women diagnosed with advanced breast cancers (T3 or T4 tumors), 
as they would be unlikely candidates for breast-conserving therapy (BCT).  Furthermore, I 
eliminated studies that focused on the influence of local management on survival after 
locoregional recurrence.  Full inclusion and exclusion criteria are available in Table 1. 
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Data Abstraction and Synthesis 
I abstracted the data from each article into a separate appraisal table and rated them for quality 
of the study and strength of evidence.  These data included the study question, study design, 
the study cohorts evaluated (based on stage, age, and type of local intervention), 
inclusion/exclusion criteria, comparability of comparison groups, primary and secondary 
outcomes assessed, author definition of outcomes, length of time allowed for outcome to occur, 
method of outcome measurement, potential confounders, statistical analysis, and study findings.  
I assigned quality ratings based on the appropriateness of study cohort and comparison groups, 
potential for selection and measurement bias (both intervention and outcome), possible 
confounders and how they were addressed, appropriateness of data analysis, power of the 
study, clinical relevance, internal and external validity, and overall relevance in relation to the 
initial study question.  I graded the evidence using the composite results of the quality ratings 
and based on established definitions from the Agency for Healthcare Research and Quality 
(AHRQ).  (Table 2).  I, then, synthesized the overall outcomes and evidence grades for each of 
the studies in individual evidence tables according to each of the outcome measures. 
 
RESULTS 
The initial search yielded 121 manuscripts, I excluded 113 manuscripts based on both title and 
abstract.  I reviewed the manuscripts of the remaining eight and excluded four for the following 
reasons: study evaluated the predictors of outcomes among patients undergoing one type of 
local treatment approach; analysis did not have at least 10 years of follow-up time to outcome 
occurrence; study did not evaluate survival outcomes; and study evaluated differences in 
utilization of one type of local management versus the other, but did not assess association of 
local approach with outcomes. After conducting hand searches, I included one additional 
manuscript (Figure 1).  
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I compared the influences of local management approaches on survival outcomes for young 
breast cancer patients in five retrospective cohort studies.  The Critical appraisal tables of the 
literature and quality ratings are available in APPENDIX A.  I graded and grouped the studies 
according to primary and secondary outcomes.  The primary outcomes examined in these 
studies included overall survival (OS) and cause-specific survival (CSS); secondary outcomes 
were local recurrence (LR), locoregional recurrence (LRR), and recurrence presenting as distant 
metastasis (DM).  The final grades of the evidence along with the magnitude and direction of 
effects are presented in Table 3, and in individual outcomes tables in APPENDIX A, Tables 2-7.  
 
Local Recurrence 
The effect of local treatment approach on local recurrence (LR) was evaluated in three of the 
studies (Table 3).  Local recurrence was defined as recurrence in the ipsilateral breast, 
overlying skin, or chest wall.  Both Coulombe G, Tyldesley S, Speers C, et al.. and Beadle BM, 
Woodward WA, Tucker SL, et al. measured time to event from initial diagnosis. However, Van 
der Sangen MJC, van de Wiel FNM, Poortmans PMP, and colleagues measured time to event 
from completion of treatment, which would vary significantly depending on whether the patient 
underwent surgery or began neoadjuvant chemotherapy initially.  Beadle BM, Woodward WA, 
Tucker SL, et al. also included an additional comparison group of women who underwent post-
mastectomy radiation (MXRT).  Both Coulombe G, Tyldesley S, Speers C, et al. and Van der 
Sangen MJC, van de Wiel FNM, Poortmans PMP, et al. reported 10-year actuarial rates in 
stage I-IIB breast cancers.  Van der Sangen MJC, van de Wiel FNM, Poortmans PMP, and 
associates reported lower LR rates in the mastectomy (M) group than among those who 
received breast-conserving therapy (BCT)  (6% vs. 18.3% respectively, p<0.0001); the risk in 
the M group actually plateaued at 6% at six years.  Conversely, Coulombe G, Tyldesley S, 
Speers C, et al. did not find clinically or statistically significant differences between the BCT and 
M groups (14% and 16.6% respectively, p=0.34); a subgroup analysis of stage IA patients 
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revealed less LR among those who underwent M than those who had BCT, 4.9% versus 13.7% 
respectively, but this was not statistically significant (p=0.30). 
Beadle BM, Woodward WA, Tucker SL, and associates included patients with stage I-IIIC breast 
cancer in their analysis.  Patients diagnosed at later stages (stage IIIA or greater) are 
considered locally advanced, and therefore are not considered part of the traditional cohort 
included in earlier landmark trials.  Furthermore, they did not stratify results for LR by stage; the 
10-year actuarial LR rates for stage I-IIIC were 15.8%, 12.5%, and 7.0% for BCT, M, and MXRT 
respectively, p=0.04. A multivariate analysis to examine the relationship between local 
management and local recurrence adjusting for known or potential confounders was not 
performed. 
 
Locoregional Recurrence  
Coulombe G, Tyldesley S, Speers C, et al. and Beadle BM, Woodward WA, Tucker SL, et al.  
compared local regional recurrence (LRR) rates based on local management (Table 4); they, 
defined LRR as time from diagnosis to first ipsilateral local or regional nodal recurrence.  
Subjects’ data were censored at the earliest of the following dates:  distant relapse occurring 
>30 days before local recurrence or local regional recurrence; subsequent contralateral breast 
cancer occurring before LR or LRR; and date of death or last follow-up.  When LR or LRR 
occurred within 30 days of distant relapse, the relapses were considered concurrent and were 
recorded as occurring on the date of the earlier events.  They found no difference in 10-year 
LRR rates for patients with stage I-IIB breast cancer after breast-conserving therapy (BCT) 
versus mastectomy  (M) (17.4% and 19.1% respectively, p=0.41).  This conclusion was further 
supported by a subgroup analysis of “ideal” BCT candidates (stage IA), who had LRR rates of 
16% in BCT group versus 12.7% in M group, p=0.94. Beadle and colleagues defined LRR as 
ipsilateral local or regional nodal recurrence (including axillary, supraclavicular, infraclavicular, 
or internal mammary nodes).  All LRRs were considered events regardless of their relationship 
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in time to distant metastasis in time.  They reported a significant difference in 10-year LRR rates 
among the collective (stage I-IIIC) group 19.8% for BCT, 24.1% for M, and 15.0% for MXRT, 
p=0.05.  After stratifying by stage, LRR rates were no different in the stage I group; 18.0% in 
BCT versus 19.8% in M, p=0.56 (there were few stage I patients who underwent MXRT, so they 
were not included).  However, there was a significant difference among those with stage II 
disease 17.7%, 22.8% and 5.7% (p=0.02) in BCT, M, and MXRT respectively.  They also 
conducted a multivariate analysis identifying BCT and M as predictors of LRR among patients 
with stage II disease, hazard ratio (HR)= 3.40 (95% CI: 0.99-11.7), p=0.052 and HR=4.45 (95% 
CI: 1.36-14.6), p=0.014 respectively. 
 
Distant Metastases  
Distant Metastases (DM) were defined as time from diagnosis to first relapse beyond ipsilateral 
breast and regional lymph nodes.  Coulombe G, Tyldesley S, Speers C, et al. censored subjects 
at the time of a subsequent contralateral new primary breast cancer occurring before a distant 
relapse, date of death, or last follow-up.  They found no difference in 10-year DM rates among 
2,398 patients with stage I-IIB breast cancer; 26.9% in the BCT group versus 27.5% in the M 
group, p=0.77 (Table 5).  However, in the subgroup analysis including only “ideal” BCT patients, 
rates of DM in those who underwent BCT were 14.3% versus 24.6% in patients who underwent 
M, p=0.17.  Although this result was not statistically significant, it may be clinically relevant.  
Beadle BM, Woodward WA, Tucker SL, and colleagues reported significant differences in DM 
rates among the entire cohort (n=652) based on local treatment (Table 5).  The BCT group had 
the lowest rates of DM, 25.5% compared with 42.5% and 49.1% in the M and MXRT groups 
respectively, p<0.0001.  Once again, when they stratified by stage, they did not find a difference 
among women with stage I breast cancer (27.4% in BCT versus 27.7% in M), p=0.15. However, 
they detected a difference among those with stage II breast cancer, 19.5% versus 33.9% versus 
39.4% in the BCT, M, and MXRT groups respectively, p=0.006.   
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Van der Sangen MJC, van de Wiel FNM, Poortmans PMP, and colleagues also evaluated 
women with stage I-IIB breast cancer.  Using the life-table approach, they measured the interval 
between the date of primary treatment until diagnosis of DM, rather than the date of initial 
cancer diagnosis until DM.  They found no difference among those treated with BCT compared 
with M, 29.0% versus 33.0% respectively, p=0.083.  Interestingly, they noted that the risk of DM 
was lower in the BCT group, hazard ratio (HR)=0.75 (95% CI: 0.61-0.93) p=0.009. However, 
after seven years, risk of DM was lower in the M group and increased in the BCT group, HR= 
1.96 (1.02-3.76) p=0.044.   
 
Cause-Specific Survival 
Coulombe G, Tyldesley S, Speers C, et al. and Mahmood U, Morris C, Neuner G, et al. 
searched for differences in cause-specific survival according to the type of local management 
received.  Cause-specific survival (CSS) was defined as time between initial diagnosis and 
death when breast cancer was the primary or underlying cause of death. They found no 
difference in CSS according to local treatment among the entire cohort, which included stages I-
IIB (BCT= 79.8%, M= 74.9%; p= 0.09); and the subgroup of “ideal” BCT patients with stage IA 
cancer only (BCT= 90.8%, M= 86.0%; p= 0.41) (Table 6).     
Mahmood’s group conducted the largest retrospective analysis to date using the Surveillance 
Epidemiology and End Results (SEER) cancer registry maintained by the National Cancer 
Institute to determine whether there was a survival difference in patients aged 20-39 who 
underwent BCT compared to those who had M with or without radiation for stage I-IIB breast 
cancer. They performed both multivariate and matched pair analyses. Multivariate analysis 
revealed no difference in CSS between BCT and M, hazard ratio (HR)=0.93 (0.83-1.05), p=0.26 
(Table 6).  Matched-pair analysis confirmed that local management was not associated with 
CSS, with identical 10-year rates of 85.5%, p=0.88. 
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Overall Survival 
Overall survival (OS) was defined as death from any cause.  The time interval was measured 
from the date of diagnosis to the date of death or last visit. Beadle BM, Woodward WA, Tucker 
SL, and colleagues found significant differences in overall survival in a pooled analysis of 
patients with stage I-IIIC breast cancer (Table 7).  Patients who underwent breast-conserving 
therapy (BCT) had 80.0% 10-year OS rates compared with 60.4% in the mastectomy (M) group, 
and 57.5% in the mastectomy with radiation (MXRT) group, p=0.0003.  Stratified analysis 
revealed a clinically relevant difference in OS among those with stage I disease, with OS rates 
of 92.4% in BCT group compared to 72.0% in M group, though this was not statistically 
significant, p=0.19.  Among patients with stage II disease, the MXRT group had the highest 10-
year OS rates (85.4%), followed by the BCT group (81.0%), and the M group (63.4%), p=0.03.  
On multivariate analysis of those with stage II cancer, undergoing mastectomy alone associated 
with a poorer OS (hazard ratio= 1.72 ; 95% CI: 1.11-2.67).  
Bantema-Joppe EJ, De Munck L, Visser O, and associates conducted a retrospective analysis 
using two Dutch cancer registries containing data from 1,453 patients with stage I-IIA breast 
cancer.  They found that women who received BCT had 5% greater 10-year OS rates when 
compared to those who received mastectomy; p=0.007 (Table 7).  Survival analysis controlling 
for age at diagnosis, time period of diagnosis, pathological T stage, adjuvant chemo, adjuvant 
hormone therapy, and nodal status concluded that M was associated with poorer OS; HR=1.37 
(1.09-1.72). 
A similar study conducted by Van der Sangen and colleagues evaluating patients diagnosed 
with stage I-stage IIB breast cancer did not reveal a clinically or statistically significant difference 
in OS; 71.2% (62.4-71.6) of those who had M were alive at 10-years compared with 74.9% 
(71.7-78.1) of patients who opted for BCT, p=0.215.  It is important to note that in this particular 
study overall survival was measured from completion of treatment until death from any cause.  
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A retrospective study conducted by Mahmood U, Morris C, Neuner G, et al. evaluated outcomes 
for 14,764 young patients with stage I-IIB breast cancer.  They performed a multivariate analysis 
adjusting for year of diagnosis, age at diagnosis, race, histology, tumor grade, area of 
involvement within the breast, tumor size, number of positive LN, number of evaluated nodes, 
estrogen receptor (ER), and progesterone receptor (PR) status.  They found no difference 
between the two treatment groups with the HR for BCT being 0.93 (0.83-1.04), p=0.16.  Results 
of a matched pair analysis was consistent with the results of their multivariate analysis; 83.6% 
OS at 10 years in the M group and 83.5% in the BCT group, p=0.99.  
 
SYNTHESIS:  A summation of the findings 
 
Stage I Breast Cancer 
With all the shortcomings of a retrospective data analysis, it appears that local management is 
not associated with statistically significant differences in local recurrence (LR) among young 
women diagnosed with stage I breast cancer; though the absolute difference between the rates 
may be clinically relevant, with an 8.8% greater LR rate after BCT. Furthermore, this conclusion 
is based on data from only one study by Coulombe’s group, which reported actuarial rates.  
Local regional recurrence (LRR) rates are not clinically or statistically different among young 
women with stage I disease in any of the included studies.   Despite the lack of statistically 
significant differences in rates of distant metastasis (DM), in the two studies that evaluated 
stage I breast cancers, the mastectomy group had 10.3% higher rates of DM at 10 years in the 
study by Coulombe and colleagues.  The same study failed to reveal any statistically or clinically 
relevant difference in cause-specific survival (CSS).  Breast-conserving therapy was superior to 
mastectomy in terms of overall survival (OS), the 10 year rates of OS were 20.4% higher among 
women who opted for BCT versus those treated with M.  Although these findings did not reach 
statistical significance, they remain clinically relevant and imply that the addition of XRT may 
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actually improve survival even among women with very early-stage breast cancer.  In summary, 
actuarial rates of LR, LRR, DM, CSS and OS were not statistically different based on local 
management approaches of stage I disease. Interestingly, these results indicate that both rates 
of DM and OS may actually be better in women undergoing BCT, despite higher rates of local 
recurrence among young women undergoing BCT.  These data imply that young women with 
stage I breast cancer can safely opt for either local management approach, and some infer that 
BCT may actually improve long-term overall survival.  
 
Stage II Breast Cancer 
Primary and secondary outcomes for the subgroup of women with stage II breast cancer were 
described in only the Beadle, Woodward and Tucker study.  They did not investigate local 
recurrence (LR) rates among women with stage II breast cancer, but found that actuarial rates 
of LRR were 5% higher among women who opted for M over BCT (p-0.02) at 10 years.  
Notably, this reported statistical significance is based on three comparison groups and may 
represent the difference between mastectomy with adjuvant radiation therapy (MXRT) versus M 
or MXRT versus BCT.  However, upon further analysis, multivariate regression confirmed the 
elevated risk of LRR among women with stage II cancer undergoing M, with a greater hazard 
ratio of LRR after M HR=4.45 (95% CI: 1.36-14.6) versus BCT HR= 3.40 (95% CI: 0.99-11.7).  
Furthermore, actuarial rates of distant metastasis were 14.4% higher in patients treated with M, 
representing a clinically important and statistically significant difference between the 
interventions.  Cause-specific survival (CSS) was not reported in this study, though overall 
survival (OS) rates were significantly different among the three groups.  Superior rates of OS 
were reported in women who underwent MXRT, followed by those who received BCT; women 
who received M alone had the lowest 10-year OS rates   Absolute differences in actuarial rates 
were greatest between M and MXRT groups (22.0% higher in MXRT) and M and BCT (17.6% 
higher in BCT) groups.  In fact, MXRT only conferred a 4.4% improvement in OS over BCT.  
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Deriving from this single study, it appears that breast conserving therapy provides superior 
outcomes in terms of LRR, DM, and OS rates among young women with stage II breast cancer.  
 
EARLY-STAGE BREAST CANCER (STAGE I-II) 
 
Investigations that described the influence of local therapy on outcomes of interest in all women 
with early-stage breast cancer (stage I-II) were generally consistent, though there were some 
conflicting findings.  The evidence compiled in this review indicates that young women with 
early-stage breast cancer are either as likely or more likely to have local recurrence (LR) after 
BCT when compared to patients treated with M. (Van der Sangen MJC, van de Wiel FNM, 
Poortmans PMP et. al. and Coulombe G, Tyldesley S, Speers C, et al.)  Coulombe’s group 
found that LRR rates did not differ based on local management approaches in women 
diagnosed with stage I-II breast cancer.  (Coulombe G, Tyldesley S, Speers C, et al.)  Similarly, 
two studies that included distant metastasis (DM) as an outcome of interest failed to find any 
statistically significant or clinically relevant differences in actuarial rates of DM in those 
undergoing M versus BCT. (Van der Sangen MJC, van de Wiel FNM, Poortmans PMP et. al. 
and Coulombe G, Tyldesley S, Speers C, et al.)  Van der Sangen and colleagues elucidated an 
interesting phenomenon wherein the hazard ratio for distant metastasis (DM) was time-
dependent.  Breast-conserving therapy had an apparent protective effect against DM until year 
seven, after which BCT was associated with higher hazard ratio for DM.  This time dependent 
interaction warrants further investigation, and was not seen in other similar studies.  Cause-
specific survival was measured by Mahmood’s group and Coulombe et al.; both groups 
concluded that local management does not influence CSS in stage I-II disease. One of three 
studies that investigated overall survival in stage I-IIA disease showed a statistically significant 
difference based on local treatment approach. However, the absolute difference in actuarial 10-
year OS rates was <5%, which may not be clinically relevant. (Bantema-Joppe EJ, De Munck L, 
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Visser O, et al.)  The two other studies that examined 10-year overall survival rates included 
women with stage I-IIB breast cancer.  Neither of these studies found any clinically nor 
statistically significant differences in OS rates. (Mahmood U, Morris C, Neuner G, et al. and Van 
der Sangen MJC, van de Wiel, FNM, Poortmans, PMP, et al.)  In short, women with early-stage 
breast cancer did not have significant differences in LRR, CSS, and OS. Utilizing the available 
evidence, young women with early-stage breast cancer should be afforded the option of 
choosing the local approach of their preference since there is no difference among long-term 
survival outcomes. However, they should be counseled about the potential for increased risk of 
local recurrence after BCT.  
 
STRENGTH OF THE AVAILABLE EVIDENCE 
 
Coulombe G, Tyldesley S, Speers C, et al. conducted a retrospective study that included 
premenopausal breast cancer patients. They stratified these women by age at diagnosis; 20-39 
years and 40-49 years of age.  Comparison groups included women who had BCT (all of whom 
had adjuvant radiation) versus those who chose M with or without radiation (XRT).   They did 
not control for XRT as a separate variable since it was strongly correlated with breast 
conserving therapy; however, this may skew the actual benefit of M.  Furthermore, bivariable 
analysis revealed that women who underwent M had worse baseline prognostic factors than did 
those undergoing BCT, including more nodal involvement, central or multifocal tumors, and 
larger tumors. Although the multivariable analysis controlled for baseline prognostic factors, it 
was based on the entire cohort of women (age 20-49). Essentially, we are provided with 
actuarial rates of outcomes in women aged 20-39 who underwent M versus BCT. Because the 
multivariate analysis included women greater than 39 years of age, its results could not be 
included in the findings of our review nor contribute to recommendations. Actuarial rates do not 
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provide us with a clear understanding of the weight that mastectomy or breast-conserving 
therapy have on the outcomes of interest.  
 
Beadle BM, Woodward WA, Tucker SL, et al. retrospectively evaluated a cohort of young 
women from M.D. Anderson Cancer Center diagnosed between 1976 and 2006. Innovations in 
local and systemic treatment approaches occurred during this broad span of time.  Inclusion of 
data that was collected more than 20 years ago may not reflect the absolute contribution of 
either local therapy within the setting of the current treatment patterns.  They reported outcomes 
for the entire cohort by time period, but they did not report the outcomes of the treatment arms 
by time period. Moreover the authors reported significant findings, but did not clarify which pairs 
of the three treatment arms were significantly different.  Another important limitation of this study 
is that women with stage IIIA-C cancers were included.  Stage IIIA-C cancer is locally advanced 
disease by definition, and thus these women are not traditional candidates for BCT.  Patients 
requiring radiation therapy after M are more likely to have advanced cancers and a poorer 
baseline prognosis than are those who are satisfactorily treated with either BCT or M.  The high 
failure rate among those in the mastectomy group might be explained by the inclusion of young 
women with stage III breast cancer who may have benefitted from post-mastectomy radiation, 
namely those with large tumors (>5 cm) or those with four or more positive lymph nodes.  Lastly, 
they did not actually answer the question they posed at the beginning of the study; instead, they 
reported actuarial rates and multivariate analyses only looking for predictors of outcomes (LRR 
and OS) stratified by stage. 
 
Van der Sangen MJC, van de Wiel FNM, Poortmans PMP, and colleagues used the life-table 
approach in their retrospective study.  All outcomes were measured from the time of treatment 
completion to the time of the “event”.  The time to completion of therapy is variable as it is 
dependent on timing and requirement for adjuvant therapy.   The authors of the other studies in 
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this review measured outcomes as time from diagnosis to the occurrence of the event. 
Moreover, follow-up time for patients that underwent BCT was one year longer than for those 
who underwent M, though the authors did not explain the rationale for the discrepancy in follow-
up time.  The authors discovered a change in the trends of distant metastasis rates after BCT 
and M. Initially, BCT was superior to mastectomy, though the trends cross at year 7 post-
treatment.  Despite this clear violation of the proportional hazards rule, they conducted a 
multivariate regression analysis including both time periods.  This approach is statistically 
unfavorable as it diminishes the true magnitude and direction of the findings.  It would have 
been more appropriate to create two regression models to represent the individual time intervals 
and report the respective hazard ratios instead.  
 
Mahmood U, Morris C, Neuner G, and colleagues conducted a secondary analysis using the 
National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) database.  The 
authors conducted both multivariate regression followed by a sensitivity analysis matching 
cases and controls.  Multiple limitations of this study are attributed to the paucity of specific data 
in the SEER database. For example, the database provides information on whether patients 
received radiation therapy; however, the targets and doses are not provided. Also, the SEER 
database does not collect information on which patients received chemotherapy nor the drug 
regimens prescribed.  The authors carried out the analysis under the assumption that 
approximately the same proportion of patients in both treatment arms received chemotherapy. 
Although the SEER data provides estrogen and progesterone receptor status, prescriptions for 
hormonal therapy and patient compliance is not reported.  HER2/neu status is not captured in 
the SEER database. Patients with unfavorable prognostic factors such as HER2/neu positivity 
or triple negative status are more likely to undergo more aggressive treatment (mastectomy) 
giving this study arm worse baseline prognosis that is unaccounted for.   Despite the fact that 
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many of the study limitations are due to the shortcomings of the database and not the study 
design itself, they are unable to answer the study question with certainty.  
 
DISCUSSION 
. The results of this review are uniform among the sub-group of patients with stage I breast 
cancer and among the cohort of all patients with early-stage breast cancer. Due to the quality of 
the single study that evaluated stage II alone, we may assume that BCT and M are not different 
at the least, and that the requirement for XRT in BCT is potentially associated with improved 
survival patients at best. These findings may seem counterintuitive in light of the pooled 
analysis, which demonstrated inferior outcomes in the MXRT group; however, it is important to 
consider that the pooled analysis included women with locally advanced breast cancer (stage 
III).  Women with locally advanced breast cancer are more likely to receive adjuvant radiation 
therapy after mastectomy than women with early-stage breast cancer due to larger tumor sizes 
and/or involved lymph nodes.  Moreover, the baseline prognosis for advanced breast cancer is 
inferior to those with early-stage cancers.  The relationships between advanced breast cancer, 
increased likelihood of requiring post-mastectomy radiation, and unfavorable baseline prognosis 
are likely to cause confounding.  
 
As evidenced in this review, BCT is associated with equal or greater risk of local recurrence at 
10 years when compared with their counterparts who opt for mastectomy. (Van der Sangen 
MJC, van de Wiel FNM, Poortmans PMP, et al.). Numerous studies have suggested that 
younger women have higher rates of LR after BCT than do older women (e.g. 20).  Other 
studies comparing young women under 35 to women 35 or older who undergo BCT find that the 
rates of LRR are higher among those in the younger age group (21-22).  Excessive LR rates 
following BCT may be explained by differences in tumor biology and pathologic findings that are 
more characteristic of breast cancers diagnosed in young women. A study by P. Karlson et. al. 
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illustrates this point well, as they find higher LRR rates after M in young women (under 40) than 
in their older counterparts (23).  Taken collectively, these studies suggest that age, or the typical 
“behavior” of young breast cancers may contribute to local failure after BCT and M.   
 
Interestingly, it seems that development of LR does not translate into inferior survival outcomes.  
This may be explained by the salvage option of M at the time LR is discovered.  The absence of 
a link between LR and long-term survival outcomes was confirmed in NSABP-06. However, the 
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) conducted a retrospective 
analysis of evidence derived from prospective randomized trials with long-term follow-up.  They 
found that when surgery or radiation could attain at least 10% absolute reduction of local 
disease recurrence, significant reductions in cause-specific mortality followed (24-25).   
The divergent conclusions derived from the EBCTCG article and this study may partially be 
explained by the greater length of follow-up time. 
 
The studies in this review suggest that DM and OS rates are similar in young women treated 
with BCT.  M. Van der Saangen’s group found an interaction between time and long-term DM 
rates.  The presence of a time interaction has important implications and should be explored 
further in future studies.  It is also possible that long-term outcomes are not captured until after 
the 10-years of follow up provided in these studies.  
 
LIMITATIONS 
 
I encountered many obstacles in attempting to identify the association between local 
management and long-term outcomes for young women with early-stage breast cancer.  This 
The foundation of this review was created built upon results from retrospective cohort studies 
and the inherent limitations that come with secondary data analyses. Variations in selection of 
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study cohorts, definition of exposures and outcomes, covariates included in analysis, and 
statistical analysis strategies are not uniform across investigations.  Inconsistencies in the 
numerous layers of breast cancer diagnostics and treatments exist within and among the 
reviewed studies dilute the magnitude and certainty of our results.  
 
Selection of Comparison Groups.  The authors define “ideal BCT candidate” differently, 
emphasizing the importance of appropriate comparison group selection.  Some investigators 
defined these candidates as patients with stage I disease, stage I and II disease, and one of the 
studies even included patients with stage III disease.  Landmark randomized trials of BCT vs. M 
did not include stage III breast cancer, which is considered locally advanced.  Women with 
advanced breast cancers are not typical candidates for BCT unless they have a good response 
to neoadjuvant chemotherapy.  
 
Management of the axilla.  Axillary nodal status is one of the most important predictors of 
prognosis in breast cancer.  Innovations in axillary management and staging complicated 
secondary analyses that included patients treated before, during, and/or after the adoption of 
sentinel lymph node biopsies.  Aggressive axillary dissections were carried out in all patients 
prior to this practice; sentinel lymph node biopsy has largely saved women without clinical 
evidence of axillary disease from a highly morbid procedure. Conversely, some sampled 
sentinel nodes with small foci of micrometastasis and small macrometastasis could have been 
missed by traditional staining methods prior to the use of advanced immunohistochemistry 
techniques.. Women with undetected micrometastasis or small macrometastsis received no 
further surgical intervention, even though the guidelines would have recommended that these 
women undergo complete axillary dissection.  
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Surgical margins and radiation therapy.  The extent of surgical resection varied in both BCT and 
M within and among studies. Some examined simple mastectomy, which includes the breast 
mound and nipple areolar complex, versus modified radical mastectomy, which also includes full 
axillary dissection.  The extent of margins in breast-conserving therapy likely varied within 
studies since they were derived from registry data.  Breast-conserving therapy includes 
lumpectomy, quandrantectomy, and in some cases multiple lumpectomies within the same 
breast.  Quandrantectomy,is a resection of the breast quadrant that includes both tumor and 
healthy tissue, often employed in patients with multifocal disease. On the other hand, 
lumpectomy, involves taking a minimal amount of healthy tissue around the tumor in order to 
obtain clean margins; recommended margins also differ between institutions (usually 1mm-
2mm).  Targets for radiation include tumor bed and axillary nodal levels; dosing and boost 
treatments varied over the time of the studies, as did the protocols. 
 
Neoadjuvant chemotherapy.  A majority of the studies did not include women that were treated 
with neoadjuvant chemotherapy (chemotherapy before surgery), which is can effectively 
downstage patients and influence local treatment approach.  This sequence is often employed 
in order to make a tumor more amenable to treatment with BCT.   Chemotherapy (either 
neoadjuvant and adjuvant) is also known to reduce local and locoregional recurrence rates in 
women who have BCT significantly, even in node negative patients (26). Moreover, patients 
with close or positive margins who are treated with conservative surgery and radiation have an 
increased risk of breast recurrence that is delayed by adjuvant systemic therapy (27).  Failure to 
adjust for chemotherapy and other systemic treatments may confound results, attributing 
survival benefit to local treatment rather than the additional contribution of systemic therapy.  
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Hormone receptor status and targeted therapy.  Assays for hormone receptor overexpression 
on cancer cells has led to targeted therapies in breast cancer. Hormone receptor status was 
taken into account in a few of the studies.  Some of the authors included hormone receptor 
status in the analysis even though this information was available for recently diagnosed study 
subjects. Most of the studies did not control for use of adjuvant hormonal therapy or types of 
hormonal therapy.  Younger breast cancer patients are more likely to have triple negative 
disease; triple negative cancer status was not included in any analysis despite its known 
unfavorable prognosis.  
 
Data analysis.  The largest limitation I encountered was in interpreting actuarial rates, since they 
fail to account for potential confounders, the influence of local management on the baseline 
natural history of breast cancer, and in light of current adjuvant therapies.  Although actuarial 
rates help us identify trends, they do not allow us to explore possible confounders that may be 
the driving forces behind these observations. The aforementioned discrepancies could 
potentially decrease the magnitude of any appreciated variances between the two groups, thus 
decreasing the internal validity. Nonetheless, they may illustrate a more accurate picture of true 
effectiveness and applicability of the interventions over a diverse spectrum of clinical practice.  
 
CONCLUSION 
Investigational studies intended to improve clinical and patient decision-making should 
demonstrate the absolute benefit provided by the intervention of interest, while also providing 
probabilities, relative risks, and hazard ratios. The absolute benefit of BCT compared with 
mastectomy in young women with breast cancer should be discussed in terms of their baseline 
risk based on clinical factors and tumor characteristics; this discussion needs to be 
accompanied by discussion of any additional benefits from adjuvant chemo and hormonal 
therapy. 
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The development of predictive models that include both clinical and pathologic characteristics 
and therapeutic interventions tools to predict benefits of adjuvant therapy are available online 
(28-29).  Although a prospective randomized control trial in survival outcomes after BCT versus 
mastectomy in young breast cancer patients would certainly help us answer this question, it is 
not feasible.  An acceptable alternative prospective observational study to study this unique 
population of breast cancer patients would either confirm or challenge the conclusion that local 
management in early-stage breast cancer is not different, even in young patients.  The 
advantage of a prospective observational study lies in its ability to pre-emptively define 
important patient demographic information, tumor characteristics, and adjuvant therapies that 
are known to influence long-term survival.  Ultimately, the value of observational and outcomes 
studies lie heavily in their ability to give us theories and a foundation for further bench and 
clinical research, rather than in a definitive answer to our questions 
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TABLES AND FIGURES 
 
Table 1. Systematic Review Inclusion and Exclusion Criteria 
  
 Inclusion Criteria  Exclusion Criteria 
Population Females 
Age <35 or <40 a the time of 
diagnosis with early stage 
invasive breast cancer 
 
DCIS 
Advanced breast cancer 
Males 
 
Interventions BCT 
 
 
Comparisons Mastectomy +/-XRT  
Outcomes Survival  
Timing ≥10 years Less than 10 years of survival 
outcomes 
Settings Western Nations 
Published in the English 
language 
 
 
Study Design Retrospective cohort studies 
published within the last 10 
years 
 
*DCIS- Ductal Carcinoma; BCT- Breast conserving therapy; XRT- radiation therapy 
 
 
 
 
 
 
 
 
 
29 
 
Table 2. AHRQ Grades of Evidence 
 
GRADE DEFINITION 
High 
High confidence that the evidence reflects the true effect. Further research 
is very unlikely to change our confidence in the estimate of effect. 
Moderate 
Moderate confidence that the evidence reflects the true effect. Further 
research may change our confidence in the estimate of the effect and may 
change the estimate. 
Low 
Low confidence that the evidence reflects the true effect. Further research 
is likely to change our confidence in the estimate of the effect and is likely 
to change the estimate. 
Insufficient 
Evidence either is unavailable or does not permit estimation of an effect. 
Sources: {Owens, JCE 2009}{AHRQ 2007} 
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EVIDENCE TABLES 
 
Table 3. Effect of Local Management on Local Recurrence (LR) 
 
EVIDENCE PROFILE: COMPARATIVE 10 YEAR LR AFTER BCT VS. 
MASTECTOMY IN YOUNG BREAST CANCER PATIENTS 
 
NO. OF  
PATIENTS 
STUDY 
DESIGN 
STUDY 
QUALITY 
MAGNITUDE OF EFFECT 
(AND/OR PRECISION) 
OVERALL 
GRADE OF THE 
EVIDENCE 
STUDY: Coulombe G, Tyldesley S, Speers C, et al.  
540 Fair  Poor Stage I-IIB: (20-39 yo) 
BCT= 14% 
MRM= 16.2% 
P= 0.34 
Stage IA: (20-39 yo) 
BCT= 13.7% 
MRM= 4.9% 
P= 0.30 
Low 
STUDY: Beadle BM, Woodward WA, Tucker SL, et al.  
652 Poor Poor Stage I-IIIC:  
BCT=15.8% 
M=12.5% 
MXRT=7.0% 
P=0.04 
*LR not stratified by stage 
Low 
STUDY: Van der Sangen MJC, van de Wiel, FNM, Poortmans, PMP.   
1451 Poor Poor Stage I-IIB: 
BCT: 18.3% (14.9-21.7) 
M: 6.0% (3.5-8.5) 
p<0.0001 
Low 
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Table 4. Effect of Local Management on Local Regional Recurrence (LRR) 
 
EVIDENCE PROFILE: COMPARATIVE10 YEAR LRR AFTER BCT VS. 
MASTECTOMY IN YOUNG BREAST CANCER PATIENTS 
 
NO. OF  
PATIENTS 
STUDY 
DESIGN 
STUDY 
QUALITY 
MAGNITUDE OF EFFECT 
(AND/OR PRECISION) 
OVERALL 
GRADE OF THE 
EVIDENCE 
STUDY: Coulombe G, Tyldesley S, Speers C, et al.  
540 Fair Poor Stage I-IIB: (20-39 yo) 
BCT= 17.4% 
MRM= 19.1% 
p= 0.41 
Stage IA: (20-39 yo) 
BCT= 16.0% 
MRM= 12.7% 
p= 0.94 
Low 
STUDY: Beadle BM, Woodward WA, Tucker SL, et al.  
652 Poor Poor Stage I-3C:  
BCT= 19.8% 
M= 24.1% 
MXRT=15.0% 
p=0.05 
Stage I: 
BCT= 18.0% 
M= 19.8% 
MXRT= Not included 
p= 0.56 
Stage II: 
BCT= 17.7% 
M= 22.8% 
MXRT= 5.7% 
p= 0.02 
Multivariate for Stage II:  
M HR= 4.45 (1.36-14.6); 
p=0.014 
BCT: HR= 3.40 (0.99-11.7); 
p= 0.052 
Low 
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Table 5. Effect of Local Management on Distant Metastasis (DM) 
 
EVIDENCE PROFILE: COMPARATIVE 10 YEAR DM AFTER BCT VS. 
MASTECTOMY IN YOUNG BREAST CANCER PATIENTS 
NO. OF  
PATIENTS 
STUDY 
DESIGN 
STUDY 
QUALITY 
MAGNITUDE OF EFFECT 
(AND/OR PRECISION) 
OVERALL 
GRADE OF THE 
EVIDENCE 
STUDY: Coulombe G, Tyldesley S, Speers C, et al. 
540 Fair  Poor Stage I-IIB: (20-39 yo) 
BCT= 26.9% 
MRM= 27.5% 
p=0.77 
Stage IA: (20-39 yo) 
BCT= 14.3% 
M= 24.6% 
p= 0.17 
Low 
STUDY: Beadle BM, Woodward WA, Tucker SL, et al.  
652 Poor Poor Stage I-IIIC:  
BCT= 25.5% 
M=42.5% 
MXRT= 49.1% 
p<0.0001 
Stage I: 
BCT= 27.4% 
M= 27.7% 
MXRT= Not included 
p= 0.15 
Stage II: 
BCT= 19.5% 
M= 33.9% 
MXRT= 39.4% 
p= 0.006 
Low 
STUDY: Van der Sangen MJC, van de Wiel, FNM, Poortmans, PMP.  
1451 Poor Poor Stage I-IIB: 
M: 33.0%  
BCT: 29.0%  
p= 0.0831 
Treatment- year 7: 
BCT: HR= 0.75 (0.61-0.93)  
p=0.009 
Year 7 onwards: 
BCT: HR=1.96 (1.02-3.76)  
p=0.044 
Multivariate 
BCT: HR=0.97 (0.78-1.20) 
p= 0.771 
Low 
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Table 6. Effect of Local Management on Cause-Specific Survival (CSS) 
 
EVIDENCE PROFILE: COMPARATIVE 10 YEAR CSS AFTER BCT VS. 
MASTECTOMY IN YOUNG BREAST CANCER PATIENTS 
NO. OF  
PATIENTS 
STUDY 
DESIGN 
STUDY 
QUALITY 
MAGNITUDE OF EFFECT 
(AND/OR PRECISION) 
OVERALL 
GRADE OF THE 
EVIDENCE 
STUDY: Coulombe G, Tyldesley S, Speers C, et al.  
540 Fair Poor Stage I-IIB: (20-39 yo) 
BCT= 79.8% 
MRM= 74.9% 
P= 0.09 
Stage IA: (20-39 yo) 
BCT= 90.8% 
M= 86.0% 
P= 0.41 
Low 
STUDY: Mahmood U, Morris C, Neuner G, et al.  
14,764 Fair/Poor Poor Stage I-IIB:  
M: HR=1.00 
BCT: HR= 0.93 (0.83-1.05)  
p=0.26 
Matched pair analysis: 
M= 85.5%  
BCT= 85.5%  
p=0.88 
Low/Moderate 
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Table 7. Effect of Local Management on Overall Survival (OS) 
 
 
EVIDENCE PROFILE: COMPARATIVE 10 YEAR OS AFTER BCT VS. 
MASTECTOMY IN YOUNG BREAST CANCER PATIENTS 
 
NO. OF  
PATIENTS 
STUDY 
DESIGN 
STUDY 
QUALITY 
MAGNITUDE OF EFFECT 
(AND/OR PRECISION) 
OVERALL 
GRADE OF THE 
EVIDENCE 
STUDY: Beadle BM, Woodward WA, Tucker SL, et al. 
652 Poor Poor Stage I-IIIC:  
BCT= 80.0% 
M=60.4% 
MXRT= 57.5% 
P=0.0003 
Stage I:  
BCT= 92.4% 
M= 72.0% 
MXRT= Not included 
P= 0.19 
Stage II: 
BCT=81%  
M= 63.4% 
MXRT= 85.4% 
p= 0.03 
M: HR= 1.72 (1.11-2.67) 
p=0.015  
Low 
STUDY: Bantema-Joppe EJ, De Munck L, Visser O, et al.   
1453 Poor Poor Stage I-IIA: 
M: 78% 
BCT: 83% 
p=0.007 
M: HR= 1.37 (1.09-1.72)  
Low 
STUDY: Van der Sangen MJC, van de Wiel, FNM, Poortmans, PMP.   
1451 Poor Poor Stage I-IIB: 
M: 71.20% (62.4-71.6) 
BCT: 74.9% (71.7-78.1) 
p=0.215 
Low 
STUDY: Mahmood U, Morris C, Neuner G, et al.  
35 
 
14,764 Fair Fair/Poor Stage I-IIB: 
Matched pair analysis  
M= 83.6%  
BCT= 83.5% 
p=0.99 
Multivariate analysis 
M=1.00 
BCT= 0.93 (0.83-1.04) 
p=0.16 
Low/Moderate 
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Figure 1. Search Results 
 
 
 
 
  
Hand search 
After exclusion 
on abstract 
Exclusion on title 
PUBMED search 
121 
manuscripts 
identified 
8 manuscripts 
remained 
4 manuscripts 
remained 
5 manuscripts 
total 
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APPENDIX A. APPRAISAL TABLES 
 
Table 1. Coulombe, et al. 
 
STUDY INFOMRATION 
Study Citation Coulombe G, Tyldesley S, Speers C, et al. Is Mastectomy 
superior to Breast-conserving treatment for young women? Int. 
J.  Radiation Oncology Biol. Phys. 2007; 67(5): 1282-1290. 
Funding No COI reported 
Country of Origin Canada (B.C.) 
STUDY QUESTION 
QUESTION Is Modified Radical Mastectomy (MRM) superior to Breast 
Conserving Therapy (BCT) in terms of local recurrence, local 
regional recurrence, distant recurrence and breast cancer 
specific survival in a cohort of young women with early-stage 
invasive breast cancer? 
POPULATION Young women diagnosed with early-stage breast cancer in 
British Columbia 
Inclusion criteria 
Age 
Stage 
T 
N 
Histologic Subtypes 
 
20-49 
Stage I-II (AJCC Stage I-IIB) 
pT1/T2 
N0/1/NX 
Ductal, Lobular, Other 
Exclusion criteria Locally advanced or metastases (T3-4; N2-N3; M1), 
neoadjuvant chemo or RT, primary breast sarcomas or 
lymphomas, prior DCIS or LCIS or other cancers, nodal RT 
INTERVENTION BCT – defined as any open surgery of the breast less than a 
total mastectomy 
COMPARISON Modified Radical Mastectomy (MRM) (+/-XRT) 
OUTCOME Local recurrence (LR) 
Local recurrence (LRR) 
Distant relapse-free survival (DRFS)  
Breast cancer specific survival (BCSS) 
TIMING 
Years of diagnosis 
Stratified? 
 
1989-1998 
No 
TIME FORWARD 10 years 
Median: 9 years 
STUDY DESIGN Retrospective Cohort study 
SELECTION OF COHORTS  
 
British Columbia Breast Cancer Outcomes Unit (BCOU) 
database 
BCT vs. MRM, early stage patients  
POPULATION CHARACTERISTICS 
N 2,398 (BCT= 1597; MRM=801-> 64/801=+XRT) 
20-39 years old (N=540; BCT= 356; MRM= 184) 
Age 
   
 
Range: 20-49  
Stratified: yes 
Stratification:  
20-39 
40-49 
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Race Not reported/controlled for 
SES Not reported/controlled for 
HR status assessed ER ONLY 
Hormone therapy Yes 
Chemotherapy Yes, adjuvant only 
POTENTIAL FOR SELECTION BIAS? 
(+, ++, +++) 
(Based on appropriate selection of 
cases or cohorts and controls, 
descriptive demographics, eligibility 
criteria (and how chosen), and initial 
comparability of groups) 
++ 
 
Logistic regression was carried out only on patients without 
missing data for the included variables and with a minimum of 
10 years follow-up. 
OUTCOME MEASUREMENT 
Definition of outcome  LR: time from diagnosis to recurrence in ipsilateral breast, 
overlying skin, or chest wall. 
LRR: time from diagnosis to first ipsilateral local or regional 
nodal recurrence. 
Censored at the earliest of the following dates:  distant relapse 
occurring >30 days before LR or LRR, subsequent 
contralateral breast cancer occurring before LR/LRR, date of 
death or last follow-up. When LR/LRR occurred within 30 days 
of distant relapse, the relapses were considered concurrent 
and were recorded as occurring on the date of the earlier 
events.  
DRFS: time from diagnosis to first relapse beyond ipsi breast 
and regional lymph nodes. 
Censored at the time of a subsequent contralateral new 
primary breast cancer occurring before a distant relapse, date 
of death, or last follow-up. 
BCSS: time between initial diagnosis and death when breast 
cancer was the primary or underlying cause of death. 
Method of Outcome Assessment  
How often? 
Equal, valid, reliable? 
Outcome data reported in database 
 
Unclear since voluntary data.  
Length of follow-up time +++ 
POTENTIAL FOR MEASUREMENT 
BIAS? (+, ++, +++) 
+/++;  
Measurement of exposure: 
No set definition of ”extensive DCIS”.  
BCOU includes centrally reviewed and non-centrally reviewed 
path reports. 
One of variables is absence or presence of “noticeable DCIS”? 
Again unclear how this is measured/defined. 
XRT does differed between groups and within groups 
CONFOUNDING 
Quality of intervention Not likely to be different 
Confounders and how each was 
addressed  
1. DID NOT CONTROL FOR XRT in 
mastectomy group since strongly related to 
surgery, kept all mastectomy +XRT in 
analysis-> controlled for margin status since 
patients requiring post-M XRT are likely to 
have positive chest wall margins. 
2. MRM patients had worse prognostic factors:  
larger tumors, ore nodal involvement, 
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“noticeable DCIS”, central or mutifocal 
lesions. 
POTENTIAL FOR CONFOUNDING? 
(+, ++, +++)  
++ 
STATISTICAL ANALYSIS 
Statistical Analysis Conducted a subgroup analysis on “ideal BCT candidates”= 
tumor size ≤ 2cm, pN0, clear surgical margins, no extensive 
DCIS= AJCC Ia 
 
Survival analysis for using forward binary logistic regression 
(b/c violated proportional hazards). Type of surgery was last to 
include in regression mode-> includes women 40-49. Those 
with minimum of 10 year follow-up and no missing values.  
Powered to show difference? 
 
Not stated a-priori 
Variables controlled for in regression 
model 
Age, size of tumor, tumor location, number of positive nodes, 
ER status, grade, LV status, margin status, primary histology, 
presence or absence of noticeable DCIS, and +/- of initial 
adjuvant chemo or hormone therapy. 
RESULTS 
LRFS 
Results In young study cohort (20-39) 
BCT= 86% 
MRM= 83.8% 
P= 0.34 
 
In ideal candidates (20-39) 
BCT= 86.3% 
MRM= 95.1% 
P= 0.30 
Magnitude  3.8% in study cohort; 8.8% in ideal 
Direction Study (I-IIB): slightly favors BCT; ideal(IA) favors MRM 
Statistically significant? No 
Clinically relevant? Yes, in ideal subgroup 
LRRFS 
Results In young study cohort (20-39) 
BCT= 82.6% 
MRM= 80.9% 
P= 0.41 
 
In ideal candidates (20-39) 
BCT= 84.0% 
MRM= 87.3% 
P= 0.94 
Magnitude  I-IIB: 1.7%; 1a: 3.3% 
Direction I-IIB group favors BCT; IA group favors MRM 
Statistically significant? No 
Clinically relevant? No 
DRFS 
Results In young study cohort (20-39) 
BCT= 73.1% 
MRM= 72.5% 
P=0.77 
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In ideal candidates (20-39) 
BCT= 85.7% 
M= 75.4% 
P= 0.17 
Magnitude  I-IIB: <1%; IA: 9.3% 
Direction Favors BCT in ideal candidates (1a) 
Statistically significant? No 
Clinically relevant? Yes 
BCSS 
Results In young study cohort (20-39) 
BCT= 79.8% 
MRM= 74.9% 
P= 0.09 
 
In ideal candidates (20-39) 
BCT= 90.8% 
M= 86.0% 
P= 0.41 
Magnitude  Stage I-IIB: 4.9%; Stage IA: 4.8% 
Direction Favors BCT in both groups 
Statistically significant? Almost in I-IIB group 
Clinically relevant? Yes 
CONCLUSIONS/COMMENTS 
Overall conclusions/interpretation 
(include consistency with other 
studies; biologic plausibility; 
conflicts of interest; selective 
endpoint reporting; costs; potential 
harms; patient decision making 
preferences) 
Logistic regression was carried out only on patients without 
missing data for the included variables and with a minimum of 
10 years follow-up. 
QUALITY RATING OF STUDY: GOOD, FAIR, POOR 
Selection of cohorts ++ 
Adjustment for Confounding + 
Measurement + 
Statistical analysis + 
Internal validity ++ 
External validity/Generalizability + 
STUDY QUALITY SCORE Poor 
STRENGTH/GRADE OF EVIDENCE: HIGH, MODERATE, LOW 
Study Design ++ 
Study Quality + 
Consistency + 
Directness + 
Precision Unknown 
STRENGTH OF EVIDENCE (GRADE) Low 
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Table 2. Beadle, et al. 
 
STUDY INFOMRATION 
Study Citation Beadle BM, Woodward WA, Tucker SL, et al. Ten-Year 
recurrence rates in young women with breast cancer by 
locoregional treatment approach. Int. J. Radiation Oncology 
Biol. Phys. 2009; 73(3): 734-44. 
 
Funding No COI reported 
Country of Origin USA 
STUDY QUESTION 
QUESTION Effect of local management comparing  Breast-cnserving 
therapy (BCT) vs. Mastectomy (M) vs. Mastectomy + radiation 
(MXRT) on 10 year rates of local recurrence (LR), local 
regional recurrence (LRR), distant metastases (DM) and 
overall survival (OS) survival in a cohort of young women with 
early-stage invasive breast cancer? 
POPULATION Young women treated for early-stage breast cancer at MD 
Anderson hospital. 
Inclusion criteria 
Age 
Stage 
 
 
 
 
T 
N 
Histologic Subtypes 
 
<35 years old at dx 
Stage I-III (using 2002 AJCC-> Stage I-IIIC) 
*patients who got neoadjuvant chemo-> most advanced stage 
used (clinical or pathological) 
patients with adjuvant chemo-> pathologic stage used 
 
T: 1-4 
N: 1-3 
Invasive ductal 
Invasive lobular 
Invasive mixed 
Unknown/other 
Exclusion criteria Inflammatory breast cancer 
DCIS 
Sarcoma 
Unknown primary 
BCT (without XRT) 
Mets within 6 months of diagnosis 
Did not receive a definitive surgery 
INTERVENTION BCT  
COMPARISON M vs. MXRT 
OUTCOME Local recurrence (LR) 
Local recurrence (LRR) 
Distant metastases (DM)  
Overall survival (OS) 
TIMING 
Years of diagnosis 
Stratified? 
 
1973-2006 
Yes, by decade of treatment:  
1973-1979 
1980-1989 
1990-1999 
2000-2006 
TIME FORWARD 10 years 
Range: 2-411 
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Median: 91 months 
STUDY DESIGN Retrospective Cohort study 
SELECTION OF COHORTS  
 
MD Anderson database  
<35 years old at dx grouped into BCT vs. M vs. MXRT 
Women with MXRT probably not candidates for BCT, should 
this comparison group be included? 
POPULATION CHARACTERISTICS 
N 652 (BCT= 196; M=237; MXRT=234) 
Age 
   
 
Range: 16-35  
Median: 33 
Stratified: yes 
Stratification: 
≤19 
20-24 
25-29 
30-35 
Race 
 
 
White/Caucasian (62%) 
Black/AA (14.8%) 
Hispanic (20.2%) 
Other (3.0%) 
SES Not reported/controlled for 
HR status assessed ER and PR 
Most patients not evaluated for her-2 status, so not reported 
Hormone therapy Yes 
Chemotherapy Yes 
POTENTIAL FOR SELECTION BIAS? 
(+, ++, +++) 
(Based on appropriate selection of 
cases or cohorts and controls, 
descriptive demographics, eligibility 
criteria (and how chosen), and initial 
comparability of groups) 
++, comparison groups are not equivalent.  Patients requiring 
MXRT are not likely candidates for BCT.  Furthermore “ideal 
BCT candidates” have smaller tumors (<5cm); this analysis 
includes patients with T3 (>5cm) who have inherently worse 
prognosis. 
OUTCOME MEASUREMENT 
Definition of outcome  All pathologic endpoints were calculated as interval between 
pathologic diagnosis of primary cancer and event of interest. 
LR: Recurrence in ipsilateral breast chest wall or overlying 
skin.   
LRR: ipsilateral local or regional nodal recurrence (including 
axillary, supraclavicular, infraclavicular, or internal mammary 
nodal beds). All LRRs were considered events regardless of 
their relation to DM in time.  
DM: recurrence in any other site. 
OS: death from any cause 
Method of Outcome Assessment  
How often? 
Equal, valid, reliable? 
Reviewed records. No info on institutional follow-up protocols 
or changes in surveillance over different time periods.  
Length of follow-up time +++ 
POTENTIAL FOR MEASUREMENT 
BIAS? (+, ++, +++) 
++ 
CONFOUNDING 
Quality of intervention ++, all patients seen and treated at one of the best cancer 
hospitals in the nation.  
Confounders and how each was 
addressed  
Only controlled for variables that were borderline/significant on 
bivariate analysis (p≤0.1) 
Stage I patients who had MXRT were few so not included in 
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subgroup analysis (Stage I: M vs. BCT only) 
POTENTIAL FOR CONFOUNDING? 
(+, ++, +++)  
+++ 
STATISTICAL ANALYSIS 
Statistical Analysis 10 year actuarial rates of LRR, DM, OS were calculated using 
KM statistic and comparisons between groups were calculated 
using log-rank test. 
 
Multivariate analysis using forward stepwise Cox regression 
(violated proportional hazards assumption). Only controlled for 
variables that were borderline/significant on bivariate analysis 
(p≤0.1)) 
 
Powered to show difference? Not stated a-priori 
Variables controlled for in regression 
model 
Unclear which univariate analysis was used to determine 
variables to be included in multivariate analysis. 
RESULTS 
LR 
Overall population (n=652; BCT= 196; M=237; MXRT=234) 
10 year actuarial rates 
 
BCT=15.8% 
M=12.5% 
MXRT=7.0% 
P=0.04 
**Did not stratify by stage for LR 
Magnitude  8.8% for BCT; 5.5% for M  
Direction Favors MXRT 
Statistically significant? Yes 
Clinically relevant? Yes 
LRR 
Overall population (n=652; BCT= 196; M=237; MXRT=234) 
10 year actuarial rates 
 
BCT= 19.8% 
M= 24.1% 
MXRT=15.0% 
P=0.05 
Magnitude  4.8% for BCT; 9.1% for M 
Direction Favors MXRT 
Statistically significant? Yes 
Clinically relevant? Yes 
Stage I (n=101; BCT=53; M=42) 
10 year actuarial rates 
 
BCT= 18.0% 
M= 19.8% 
MXRT= Not included 
P= 0.56 
Stratified by chemo: 
No Chemo: BCT= 33.3%; M= 25.5% 
P=0.23 
Chemo: BCT= 12.0%; M= 9.0% 
P= 0.72 
(chemo group had more high grade tumors; p=0.005) said all 
other factors not sig different but didn’t report HRs) 
Multivariate analysis No adjuvant chemo: HR=2.73 (1.06-7.04); p=0.037 
No hormone therapy HR= 2.54 (0.98-6.56); p= 0.055 
Magnitude  Only when stratified by chemo 
Direction No chemo favors BCT; +Chemo favors M 
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Statistically significant? No 
Clinically relevant? Yes 
Stage II (n= 296) 
10 year actuarial rates 
 
BCT= 17.7% 
M= 22.8% 
MXRT= 5.7% (despite advanced N stage (p=0.004); and use 
of neoadjuvant chemo (p<0.0001)) 
P= 0.02 
Multivariate analysis M Alone: HR= 4.45 (1.36-14.6); p=0.014 
BCT: HR= 3.40 (0.99-11.7); p= 0.052 (34 got neoadjuvant 
chemo, 68 no neoadjuvant; p= 0.29) 
Grade 3: HR= 2.24 (1.19-4.23); p=0.012 
Magnitude  12% for BCT; 17.1% for M 
Direction Favors MXRT>BCT>M 
Statistically significant? Yes 
Clinically relevant? Yes 
Stage III (n=262) 
10 year actuarial rates 
 
BCT= 28.4% 
M= 23.9% 
MXRT= 18.4% 
P= 0.13 
Multivariate analysis M Alone: HR= 2.37 (1.24-4.51); p=0.009 
≥10 +LN: HR= 2.50 (1.36-4.60); p= 0.003 
older age: HR= 0.91 (0.85-0.99); p=0.021 
No neoadjuvant chemo: HR= 0.59 (0.31-1.09); p=0.094 
Magnitude  10% for BCT; 5.5% for M 
Direction Favors MXRT>M>BCT 
Statistically significant? No 
Clinically relevant? Yes 
DM 
Overall population (n=652; BCT= 196; M=237; MXRT=234) 
10 year actuarial rates 
 
BCT= 25.5% 
M=42.5% 
MXRT= 49.1% 
P<0.0001 
Magnitude  17.0% for M; 24.4% for MXRT 
Direction Favors BCT>M>MXRT 
Statistically significant? Yes 
Clinically relevant? Maybe, but patients with MXRT tend to be more advanced 
than candidates for BCT 
Stage I (n=101; BCT=53; M=42) 
10 year actuarial rates 
 
BCT= 27.4% 
M= 27.7% 
MXRT= Not included 
P= 0.15 
Multivariate analysis Did not report 
Magnitude  0.3% 
Direction Favors M 
Statistically significant? No 
Clinically relevant? No 
Stage II (n= 296) 
10 year actuarial rates 
 
BCT= 19.5% 
M= 33.9% 
MXRT= 39.4% 
45 
 
P= 0.006 
Multivariate analysis Did not report 
Magnitude  14.4% for M; 20.1% for MXRT 
Direction Favors BCT 
Statistically significant? Yes 
Clinically relevant? Yes?  
Stage III (n=262)  
10 year actuarial rates 
 
BCT= 36.2% 
M= 58.3% 
MXRT= 54.0% 
P= 0.08 
Multivariate analysis Did not report 
Magnitude  22.1% for M; 17.8% for MXRT 
Direction BCT>MXRT>M 
Statistically significant? almost 
Clinically relevant? Yes 
OS 
Overall population (n=652; BCT= 196; M=237; MXRT=234) 
10 year actuarial rates 
 
BCT= 80.0% 
M=60.4% 
MXRT= 57.5% 
P=0.0003 
Magnitude  22.5% for BCT; 2.9% for M 
Direction BCT>M>MXRT 
Statistically significant? yes 
Clinically relevant? Yes 
Stage I 
10 year actuarial rates 
 
BCT= 92.4% 
M= 72.0% 
MXRT= Not included 
P= 0.19 
Multivariate analysis +Hormone therapy: HR= 2.17 (0.90-5.23); p=0.084 
Magnitude  20.4% 
Direction Favors BCT 
Statistically significant? No 
Clinically relevant? Yes, maybe just not powered to show a difference 
Stage II (n= 296) 
10 year actuarial rates 
 
BCT=81%  
M= 63.4% 
MXRT= 85.4% 
p= 0.03 
Multivariate analysis M alone: HR= 1.72 (1.11-2.67); p=0.015 
+LN: HR= 1.52 (0.97-2.37); p= 0.067 
Magnitude  -4.3% for BCT; -22.0% for M 
Direction MXRT>BCT>M 
Statistically significant? Yes 
Clinically relevant? Yes 
Stage III (n=262) 
10 year actuarial rates 
 
BCT= 64.4% 
M= 46.6% 
MXRT= 48.4% 
P= 0.16 
Multivariate analysis  M alone: HR= 1.58 (1.02-2.45); p= 0.041 
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≥ 4+ nodes: HR= 2.29 (1.42-3.67); 0.001 
≥ 10+ nodes: HR= 1.47 (0.95-2.26); p=0.082 
No adjuvant chemo; HR= 1.70 (1.00-2.87); p=0.049 
ER negative: HR= 1.92 (1.28-2.87) 
BCT: 0.54 (0.29-0.99) 
No neoadjuvant chemo: 0.41 (0.25-0.66); p<0.0001 
Magnitude -16.8% for M; -16% for MXRT 
Direction BCT>MXRT>M 
Statistically significant? yes 
Clinically relevant? Yes for BCT but no big diff b/w M and MXRT 
CONCLUSIONS/COMMENTS 
Overall conclusions/interpretation 
(include consistency with other 
studies; biologic plausibility; 
conflicts of interest; selective 
endpoint reporting; costs; potential 
harms; patient decision making 
preferences) 
Although it would be helpful to determine benefit based on 
subgroups with each combination of local management, it is 
inappropriate to do so retrospectively since the decision for 
type of local management results from clinical and pathologic 
characteristics.   
It would be more appropriate to determine the baseline risk for 
a particular outcome and then compare that to each local 
intervention. 
***Only single institution study: had equal exposure, or quality 
of intervention.  Since everything done according hospital 
protocol (admin of XRT, etc. ). Although protocols changed 
during different time periods.  
QUALITY RATING OF STUDY: GOOD, FAIR, POOR 
Selection of cohorts + 
Adjustment for Confounding + 
Measurement ++ 
Statistical analysis + 
Internal validity ++ 
External validity/Generalizability ++ 
STUDY QUALITY SCORE Fair/Poor 
STRENGTH/GRADE OF EVIDENCE: HIGH, MODERATE, LOW 
Study Design + 
Study Quality + 
Consistency ++ 
Directness + 
Precision +  
STRENGTH OF EVIDENCE (GRADE) Low 
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Table 3. Bantema-Joppe, et al. 
 
STUDY INFOMRATION 
Study Citation Bantema-Joppe EJ, De Munck L, Visser O, et al.  Early-
stage young breast cancer patients: Impact of local 
treatment on survival.  Int J Radiaton Oncol Bio Phys. 
2011; 81(4):e553-9. 
Funding No COI statement 
Country of Origin The Netherlands 
STUDY QUESTION 
QUESTION Does difference in local control translate into inferior 
survival after BCT in young breast cancer patients? 
POPULATION Young (<40) Dutch women diagnosed with early stage 
(up to 2A) invasive breast cancer treated with BCT or M 
(+/-XRT) between 1/89-1/05) 
Inclusion criteria 
Age 
Stage 
T 
N 
Histologic Subtypes 
 
<40 
Stage I to IIA 
pT1a-c (≤ 2 cm) 
pN0-1 (≤ 3 +LN) 
Not specified 
Exclusion criteria Distant metastases, previous history of invasive cancer 
(except non-melanoma skin cancer), and patients 
treated with neoadjuvant chemotherapy. 
INTERVENTION BCT  
COMPARISON Mastectomy 
OUTCOME Overall survival (OS) 
TIMING 
Years of diagnosis 
Stratified? 
 
January 1989-January 2005 
Yes 
1989-1994 (38.9%) 
1995-2000 (29.1%) 
2001-2004 (33.1%) 
TIME FORWARD 10 years 
Median time to outcome: 9.6 years (IQR 5.9-14.3) 
STUDY DESIGN Retrospective cohort study  
SELECTION OF COHORTS  
 
Patient data obtained from 2 Dutch population based 
cancer registries (cover 40% of pop) 
Young women <40 years old at the time of diagnosis 
with invasive early stage breast cancer who were “ideal 
candidates for BCT”  
POPULATION CHARACTERISTICS 
N 1,453 (M=504; BCT= 909) 
Age 
   
 
<40 
Median: 36.5 (IQR 33.8-38.4) 
Stratified: yes 
<35 (34%) 
35-39 (66%) 
Race Not reported/controlled for 
SES Not reported/controlled for 
HR status assessed Not routinely tested for at the beginning of the study 
period so it was not included in the analysis.  
Hormone therapy Yes 
Chemotherapy Yes 
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POTENTIAL FOR SELECTION 
BIAS? (+, ++, +++) 
(Based on appropriate selection of 
cases or cohorts and controls, 
descriptive demographics, 
eligibility criteria (and how chosen), 
and initial comparability of groups) 
+ 
OUTCOME MEASUREMENT 
Definition of outcome  OS defined as interval from date of pathologic diagnosis 
to the date of death from any outcome 
Method of Outcome Assessment  
How often? 
Equal, valid, reliable? 
Data on mortality from municipal personal records 
database last linkage Feb 2009. 
 
Length of follow-up time +++ 
POTENTIAL FOR MEASUREMENT 
BIAS? (+, ++, +++) 
+ 
CONFOUNDING 
Quality of intervention Unknown 
Confounders and how each was 
addressed  
M +XRT=(23%)-> could make mastectomy outcomes 
seem better than they are.  
Didn’t control for grade, histologic subtype, receptor 
type (unless they assume all ER+ patients got ERB or 
ovarian suppression) 
POTENTIAL FOR CONFOUNDING? 
(+, ++, +++)  
+/++ 
STATISTICAL ANALYSIS 
Statistical Analysis Multivariate cox regression survival analysis for 10 year 
OS 
Powered to show difference? 
 
Not stated a-priori 
Variables controlled for in 
regression model 
Age at diagnosis 
Period of diagnosis (year categories above) 
Pathological T stage 
Adjuvant chemo 
Adjuvant hormone therapy 
Stratified by Nodal status 
N0 vs. N1 
RESULTS 
OS 
Results Overall:  
Actuarial10 year survival rate 
M: 78% 
BCT: 83% 
Log-rank test (p=0.007) 
HR= 1.37 (CI:1.09-1.72) for M vs. BCT (HR=1) 
 
Multivariate regression (adjusted) 
Not reported 
 
N0:  
Actuarial 10 year survival rate 
M: 81%  
BCT: 84% 
Log-rank test (p=0.26) 
No diff. after M (HR=1.18; CI:0.88-1.57) vs. BCT 
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(HR=1)  
 
Multivariate regression (adjusted) 
M: 1.19 (0.89-1.58) 
BCT: 1 
Log-rank test (p= 0.25) 
 
N1:  
Actuarial 10 year survival rate 
M: 71% 
BCT: 79%   
Log-rank test (p=0.014) 
M (HR=1.62; CI:1.10-2.40) is inferior to BCT (HR=1) 
 
Multivariate regression (adjusted) 
M: 1.91 (CI: 0.89-1.58) 
BCT: 1 
Log-rank test (p=0.001) 
 
Magnitude  8% 
Direction BCT superior to M 
Statistically significant? Yes 
Clinically relevant? Yes 
CONCLUSIONS/COMMENTS 
Overall conclusions/interpretation 
(include consistency with other 
studies; biologic plausibility; 
conflicts of interest; selective 
endpoint reporting; costs; potential 
harms; patient decision making 
preferences) 
Hormone therapy improves survival  
(HR= 0.34 vs. 1); p=0.001 
M group more likely to take hormone therapy: 
Overall 18.4% vs. 13.0% p=0.005 
N2 group: 35.3% vs. 25.9% p=0.00 
Goes back to attributable benefit. How much is local 
therapy making/not making a difference? 
 
Don’t know which races were included in study but most 
likely white European females, not applicable to US 
pop. 
Overall: favors BCT* 
N0: No difference in 10yr OS for BCT 
N1: BCT> M 10 yr OS (p=0.014) 
Even after adjusting for other characteristics HR for OS 
in M= 1.91 vs. BCT= 1 (p=0.001) 
QUALITY RATING OF STUDY: GOOD, FAIR, POOR 
Selection of cohorts ++ 
Adjustment for Confounding + 
Measurement + 
Statistical analysis + 
Internal validity  
External validity/Generalizability + 
STUDY QUALITY SCORE Poor 
STRENGTH/GRADE OF EVIDENCE: HIGH, MODERATE, LOW 
Study Design + 
Study Quality + 
Consistency ++ 
Directness + 
Precision ++ 
STRENGTH OF EVIDENCE (GRADE) Low 
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Table 4. Van Der Sangen, et al. 
 
STUDY INFOMRATION 
Study Citation Van der Sangen MJC, van de Wiel, FNM, Poortmans, PMP.  
Are breast conservation and mastectomy equally effective in 
the treatment of young women with early breast cancer? Long-
term results of a population-based cohort of 1,451 patients 
aged ≤ 40 years.  Breast Cancer Res Treat. 2011;(127):207-
215. 
Funding No COI reported 
Country of Origin The Netherlands 
STUDY QUESTION 
QUESTION Long term outcomes: Local recurrence (LR), Distant 
recurrence-free survival (DRFS), and Overall survival (OS) in 
young breast cancer patients with early stage breast cancer. 
POPULATION Young women diagnosed with breast cancer (<40 years old) 
from the Netherlands 
Inclusion criteria 
Age 
Stage 
T 
N 
Histologic Subtypes 
 
<40 years old   
Stage I-IIB 
T: pT1-2 
N: 0-2 
Ductal 
lobular/mixed 
other 
Exclusion criteria Missing or incomplete data 
Stage III or IV 
Neoadjuvant chemo 
Synchronous bilateral breast cancer 
Lumpectomy without XRT 
DCIS 
INTERVENTION BCT  
COMPARISON Mastectomy 
OUTCOME LR 
DRFS 
OS 
TIMING 
Years of diagnosis 
Stratified? 
 
1988-2005 
Yes 
1988-1993 
1994-1999 
2000-2005 
TIME FORWARD 15 year follow up  
Different follow-up durations for BCT and mastectomy. 
Mastectomy: Data censored on Jan 1, 2007 
Median follow-up: 7.4 years 
BCT: Data censored on Jan 1, 2008 
Median follow-up 9.5 years 
 
STUDY DESIGN Retrospective cohort study using registry and hospital data 
SELECTION OF COHORTS  
 
Eindhoven Cancer Registry (2.4 mill in south of Netherlands.  
Data compared to data derived from 2 radiotherapy 
departments in the region. Records of patients that did not 
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have XRT were obtained from surgical departments of the 10 
regional hospitals. 
POPULATION CHARACTERISTICS 
N 1451 (M= 562; BCT= 889 ) 
Age 
   
 
≤ 40 
Median in M: 37.2 
Median in BCT: 37.4 
Stratified: yes 
Stratification:  
≤ 30 
31-35 
36-40 
Race Not reported/controlled for 
SES Not reported/controlled for 
HR status assessed Just looked at ER+/-, but did not control for receptor status 
Hormone therapy Yes 
Chemotherapy Yes 
POTENTIAL FOR SELECTION BIAS? 
(+, ++, +++) 
(Based on appropriate selection of 
cases or cohorts and controls, 
descriptive demographics, eligibility 
criteria (and how chosen), and initial 
comparability of groups) 
+++ 
comparison groups not comparable on clinical characteristics 
including: 
age, period of dx, tumor size, nodal status, tumor type, grade, 
microscopic completeness of tumor excision, radiotherapy, 
adjuvant systemic treatment. 
OUTCOME MEASUREMENT 
Definition of outcome  Measured survival from time of primary treatment instead 
of time of diagnosis. 
LR- recurrence in the ipsilateral breast, overlying skin or chest 
wall. 
DRFS- 
OS- death from any cause 
Method of Outcome Assessment  
How often? 
Equal, valid, reliable? 
 
 
BIAS-> different follow-up times based on surgical procedure 
Length of follow-up time +; not consistent 
POTENTIAL FOR MEASUREMENT 
BIAS? (+, ++, +++) 
+++ 
CONFOUNDING 
Quality of intervention Not known 
Confounders and how each was 
addressed  
Different follow-up durations for BCT and mastectomy. 
Just looked at ER+/-, but did not control for receptor status in 
multivariate analysis. 
101 records missing in M group, no records missing in BCT 
group.  Could alter results. Did not state whether this data was 
missing at random. 
POTENTIAL FOR CONFOUNDING? 
(+, ++, +++)  
+++ 
STATISTICAL ANALYSIS 
Statistical Analysis Violated proportional hazards assumption because in the first 
7 years after treatment distant recurrence was significantly 
lower for BCT group (p=0.009), but patients who survived 
without DM until 7
th
 year, risk of developing DM after year 7 
lower in M group (p=0,044). 
 
Actuarial analysis for LR (5, 10,15 year), DRFS (10 year) and 
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Overall survival (10 year) 
 
Multivariate cox proportional hazards model to assess DRFS 
ONLY!  Didn’t state how they addressed survival analysis 
since KM actuarial curves violated PH assumption. 
Powered to show difference? 
 
Not stated a-priori 
 
Variables controlled for in regression 
model 
Only adjusted for age at dx, period of dx, tumor size, axillary 
nodal status, use of adjuvant systemic treatment. 
RESULTS 
LR 
Results Actuarial LR rates  
M: 
5 year: (4.4% CI: 2.4-6.4)  
10year: (6.0% CI: 3.5-8.5) 
15 year: (6.0% CI: 3.5-8.5) -> risk plateaued at 6 years 
BCT: 
5 year: 8.3% (CI: 6.3-10.5) 
10 year: 18.3% (CI: 14.9-21.7) 
15 year: 27.9% (CI: 22.9-32.9) 
Actuarial differences between M and BCT were significant 
(p<0.0001) 
Magnitude  3.9%, 12.4%, 22.2% respectively 
Direction Favored M 
Statistically significant? Yes 
Clinically relevant? Yes, actuarial LR is higher in BCT 
DRFS 
Results Actuarial 10 year DRFS rates 
M: 67.0% (CI:62.4-71.6) 
BCT: 71.0% (67.6-74.4) 
p= 0.0831 
Actuarial 10 year HRs 
Treatment- year 7: 
M: HR=1 (standard)  
BCT: HR= 0.75 (CI:0.61-0.93)  
p=0.009 
Year 7 onwards: 
M: HR=1 (standard)  
BCT: HR=1.96 (CI: 1.02-3.76)  
p=0.044 
Multivariate 
M: HR=1 
BCT: HR=0.97 (0.78-1.20) 
p=0.771 
Magnitude  4% 
Direction Favors BCT for tx-7 year, then favors M after 7 years. 
Statistically significant? No 
Clinically relevant? Might be, would like to see trend at 5 and 15 years too 
OS 
Results Actuarial 10-year OS 
M: 71.20% (CI:62.4-71.6) 
BCT: 74.9% (CI:71.7-78.1) 
p=0.215 
Magnitude  3.7% difference 
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Direction Favors BCT 
Statistically significant? No 
Clinically relevant? Might be, would like to see trend at 5 and 15 years too 
CONCLUSIONS/COMMENTS 
Overall conclusions/interpretation 
(include consistency with other 
studies; biologic plausibility; 
conflicts of interest; selective 
endpoint reporting; costs; potential 
harms; patient decision making 
preferences) 
101 records missing in M group, no records missing in BCT 
group.  Could alter results. Did not state whether this data was 
missing at random. 
Differential follow-up time for comparison groups 
 
Distant recurrence was significantly lower for BCT group but 
patients who survived without distant mets until 7
th
 year, risk of 
developing distant mets after year 7 lower in M group 
 
Would be helpful to see the attributable benefit of surgical 
treatment after subtracting baseline risk of having each 
outcome. 
QUALITY RATING OF STUDY: GOOD, FAIR, POOR 
Selection of cohorts + 
Adjustment for Confounding + 
Measurement + 
Statistical analysis + 
Internal validity + 
External validity/Generalizability + 
STUDY QUALITY SCORE Poor 
STRENGTH/GRADE OF EVIDENCE: HIGH, MODERATE, LOW 
Study Design + 
Study Quality + 
Consistency ++ 
Directness + 
Precision + 
STRENGTH OF EVIDENCE (GRADE) Low 
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Table 5. Mahmood, et al. 
 
STUDY INFOMRATION 
Study Citation Mahmood U, Morris C, Neuner G, et al. Similar Survival 
with breast conservation therapy or mastectomy in the 
management of young women with early-stage breast 
cancer. Int J Radiaton Oncol Bio Phys. 
2012;83(5):1387-1393. 
Funding No COI statement 
Country of Origin USA 
STUDY QUESTION 
QUESTION Cause specific survival (CSS) and overall survival (OS) 
outcomes after BCT vs. Mastectomy in young women 
(<40) with invasive breast cancer.  
POPULATION SEER data derived from US population 
Inclusion criteria 
Age 
Stage 
T 
N 
Histologic Subtypes 
 
20-39 years old 
Stage I-IIB 
T1-2 (≤5 cm) 
N0-1 (≤ 3 +LN) 
Invasive Ductal Carcinoma (IDC 0-3: 8500, 8521, 8523)  
Invasive Lobular Carcinoma (ILC: 8520, 8524)   
Both (8522) 
Exclusion criteria previous history of malignancy 
missing info on extent of surgery or XRT 
lumpectomy without XRT 
died within 6 months of diagnosis 
INTERVENTION BCT  
COMPARISON Mastectomy (+/-) XRT 
OUTCOME OS Survival  
CSS Survival 
TIMING 
Years of diagnosis 
Stratified? 
 
1990-2007 
No 
TIME FORWARD 5, 10, 15 years in matched-pair. Not clear what time 
forward was in pooled, BCT and M analyses 
5.7 years (0.5-17.9) 
 
5 year:  56% of sample had 5 years of follow up time 
10 year: 23% 
15 year:  7% 
 
STUDY DESIGN Retrospective cohort study and matched pair analysis 
using SEER registry data (covers 26% of US pop).  
SELECTION OF COHORTS  
 
US females dx with invasive early stage breast cancer 
between 20-39 years old and candidates for BCT, 
ideal? 
POPULATION CHARACTERISTICS 
N 14, 764 (M=8124; BCT=6640) 
Age 
   
 
Range: 20-39 
Stratified: yes 
Stratification:   
≤ 33  
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34-36 
37-38 
39 
Race White: 64% 
Black: 11% 
Hispanic: 11% 
Asian: 11% 
Other/unknown: 1% 
SES Not reported/controlled for 
HR status assessed ER, PR only 
Hormone therapy Unknown 
Chemotherapy Unknown, made assumption 
POTENTIAL FOR SELECTION 
BIAS? (+, ++, +++) 
(Based on appropriate selection of 
cases or cohorts and controls, 
descriptive demographics, 
eligibility criteria (and how chosen), 
and initial comparability of groups) 
+ 
 
OUTCOME MEASUREMENT 
Definition of outcome  Survival defined as interval from date of diagnosis to 
date of death or last visit.  
Method of Outcome Assessment  
How often? 
Equal, valid, reliable? 
Used national cancer database.   
Contains info up until 2007. 
Follow-up is generally less frequent in patients 
undergoing M since they do not need surveillance of 
remaining breast tissue, however we don’t have info 
since data was not collected prospectively and 
frequency of follow-up in not available through SEER.  
Length of follow-up time ++; 23% had 10 year follow up 
POTENTIAL FOR MEASUREMENT 
BIAS? (+, ++, +++) 
++ 
CONFOUNDING 
Quality of intervention Unknown, but likely represents academic institutions 
with higher patient volume, cancer care coordination, 
resources etc. Requires a cancer registrar to submit 
information.  
Confounders and how each was 
addressed  
Chemotherapy-> assume that most women got chemo. 
HR status-> controlled for hormone receptor status and 
assume that ER+ females got tamoxifen.  No info on 
her-2 neu which is associated with poor outcomes prior 
to trastuzmab.  Patients with poor prognostic factors 
such as her-2 positivity or triple negative status are 
more likely to undergo more aggressive treatment 
(mastectomy) giving this study arm a poorer baseline 
prognosis that is not accounted for. 
POTENTIAL FOR CONFOUNDING? 
(+, ++, +++)  
++ 
Matched pair analysis may help alleviate confounding, 
however without info about chemo +/- hormone 
treatment, there may be inherent bias. (e.g. studies 
show that BCT+ chemo has decreased rate of LRR, any 
benefit or non-difference between BCT and M could be 
due to synergistic benefit with additional therapies. 
STATISTICAL ANALYSIS 
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Statistical Analysis 1. Multivariable analyses (proportional 
hazards regression) to determine which 
variables were independent “predictors” 
of OS and CSS using entire cohort 
(pooled). 
2. Multivariable analyses (proportional 
hazards regression) to determine which 
variables were independent “predictors” 
of OS and CSS for BCT patients and 
then M patients separately. 
3. Matched pair analysis of BCT vs. M 
(n=4,644).  Matched on age at dx, year 
of dx, grade, tumor size, # of positive 
LN,  # of evaluated LN, ER and PR. KM 
curves generated for OS and CSS, 
statistical sig. evaluated using log-rank 
tests.  
4. Subset analyses for OS and CSS of the 
matched pair cohort in each age 
quartile. 
Powered to show difference? 
 
Not stated a-priori 
 
Variables controlled for in 
regression model 
Year of diagnosis 
Age at diagnosis (converted into categorical var) 
Race  
histology 
Grade 
Area of involvement within the breast 
Tumor size (converted into categorical var) 
# positive LN (converted into categorical var) 
# nodes evaluated (categorized) 
ER 
PR 
RESULTS 
OS 
Results Pooled analysis:  
HR for OS: M=1.00; BCT= 0.93 (0.83-1.04) p=0.16 
 
Matched-pair analysis:  
5 year:  M=91.9%; BCT= 92.5%  
10 year: M= 83.6%; BCT= 83.5% 
15 year: M= 79.1%; BCT = 77.0% 
p= 0.99 
 
Magnitude  Small 
Direction Favors BCT 
Statistically significant? No 
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Clinically relevant? No  
CSS 
Results Pooled analysis:  
HR for CSS: M=1.00; BCT= 0.93 (0.83-1.05) p=0.26 
 
Matched-pair analysis:  
5 year: M= 92.5% (died or censored= 604); BCT= 
93.3% (died or censored= 445) 
 
10year: M= 85.5% (died or censored= 1178); BCT= 
85.5% (died or censored= 963) 
 
15 year: M=81.9% (died or censored= 1470); BCT= 
79.9% (died or censored= 1633) 
p= 0.88  
 
Repeated these analyses and stratified by age 
quartile, no differences.  
 
Magnitude  Small 
Direction Favors BCT 
Statistically significant? No 
Clinically relevant? No 
CONCLUSIONS/COMMENTS 
Overall conclusions/interpretation 
(include consistency with other 
studies; biologic plausibility; 
conflicts of interest; selective 
endpoint reporting; costs; potential 
harms; patient decision making 
preferences) 
Chemo: assume they all got chemo but data not 
available in SEER, had to make a lot of assumptions.  
Some important data missing.  Her status, hormone 
therapy, chemotherapy regimens are known to affect   
These could all confound the data.  Also it would be 
helpful to include triple negative status as a separate 
variable to control for. 
Pooled analysis:  
Year of diagnosis, age, race, grade, PR status, tumor 
size, # of +LN, and # of examined LN predictors of OS 
AND CSS 
Youngest quartile ≤33 had inferior OS and CSS than all 
other women. 
ER status (CSS) 
 
 
Subgroup analyses:  
 year of dx, race, grade, tumor size, and number of + 
LN were predictors of OS and CSS for BOTH BCT and 
M groups 
 
Other predictors in BCT group:  
ER status (CSS) 
 
Other predictors in M group 
# of examined LN (OS and CSS) 
age and PR status (CSS only) 
 
QUALITY RATING OF STUDY: GOOD, FAIR, POOR 
Selection of cohorts + 
Adjustment for Confounding + 
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Measurement + 
Statistical analysis ++ 
Internal validity ++ 
External validity/Generalizability ++ 
STUDY QUALITY SCORE Fair/poor 
STRENGTH/GRADE OF EVIDENCE: HIGH, MODERATE, LOW 
Study Design ++ 
Study Quality + 
Consistency ++ 
Directness + 
Precision ++ 
STRENGTH OF EVIDENCE (GRADE) Moderate/Low 
 
 
 
 
 
